Back to News
Nov 6, 2025 4:10 AM

arcoris bio raises CHF 6.3 million seed round to advance next-generation biomarker technology for digital pathology

Schlieren, Switzerland, Nov. 06, 2025 (GLOBE NEWSWIRE) --

Round co-led by Ventura Ace and ZEISS Ventures, with participation from Zürcher Kantonalbank (ZKB) and new as well as existing private investors.

MUSE®, arcoris bio's nanotechnology platform for biomarker detection and signal amplification, enables simultaneous detection of multiple biomarkers with unprecedented ease and sensitivity.

The funding will accelerate industrialization of the MUSE® platform, expansion of strategic partnerships, and launch of new products.

Schlieren, Switzerland, 6. November 2025, arcoris bio, a Swiss life science research tools and in vitro diagnostics company, has secured CHF 6.3 million in an oversubscribed seed financing round to advance the development and commercialization of its breakthrough MUSE® biomarker detection platform. The round was co-led by Ventura Ace and ZEISS Ventures, with participation from Zürcher Kantonalbank (ZKB) and both existing and new private investors.

"Attracting two lead investors with deep industry expertise is a ...